Retatrutide/Cagrilitide 10 mg + 5 mg research-grade lyophilized powder supplied in a sealed glass vial. This dual-compound formulation is studied in experimental models of metabolic regulation, appetite signaling and energy balance via incretin and amylin-related pathways.
Cagrilitide: 1415456-99-3
Retatrutide/Cagrilitide 10 mg + 5 mg
Research Overview
Retatrutide and cagrilitide are synthetic peptide analogues studied in advanced metabolic research. Retatrutide is investigated for its multi-receptor activity within incretin pathways, while cagrilitide is explored as a long-acting amylin analogue. In experimental settings, this combination is used to study appetite regulation, energy expenditure, glucose handling and metabolic signaling integration.
Primary Research Areas
- Incretin & amylin signaling pathways: used to investigate combined modulation of GLP-1, GIP, glucagon and amylin-related receptor systems in metabolic research models.
- Energy balance & appetite regulation: applied in experimental studies examining food intake behavior, satiety signaling and central–peripheral metabolic communication.
- Glucose metabolism & insulin dynamics: explored in preclinical models assessing glycemic control, insulin sensitivity and pancreatic signaling responses.
- Body-weight regulation models: studied in animal models of obesity and metabolic dysfunction to evaluate synergistic effects on adiposity and energy expenditure.
- Neuroendocrine & metabolic integration: investigated for interactions between central appetite circuits, peripheral hormone signaling and adaptive metabolic responses.
Recommended solvent — Bacteriostatic water

- Complementary Pathways: Retatrutide handles GLP-1/GIP/glucagon signaling, while Cagrilintide provides parallel amylin-based hindbrain satiety signaling.
- Investigation Only: Neither compound is FDA-approved as a combined commercial product for weight loss or diabetes, and formal synergistic dosing guidelines for a fixed 10 mg + 5 mg ratio have not been established in standard clinical prescribing information. [1]
- Are you looking for reconstitution or mixing calculations for research vials?
- Are you trying to understand clinical trial data for these specific doses?
What is cagrilintide and retatrutide?
- Triple Receptor Activation: Binds simultaneously to GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.
Drugs.com
- Energy Expenditure: The added glucagon receptor activity helps increase calorie burn and break down liver fat.
Creative Peptides +1
- Clinical Efficacy: Phase clinical trials have shown substantial average body weight reductions exceeding 24% over extended treatment periods
.
Creative Peptides +1
- Amylin Analog: Mimics human amylin, a natural hormone released by the pancreas alongside insulin to signal fullness to the brain.
- Delayed Gastric Emptying: Slows down the rate at which food leaves the stomach, prolonging post-meal satiety.
- Combination Potential: Frequently studied in synergy with incretin backbones (such as semaglutide in CagriSema or paired alongside retatrutide) to attack appetite via separate neurological pathways.
www.retaweightloss.com +3
- Gastrointestinal: Nausea, vomiting, diarrhea, and constipation.
- Other Responses: Potential for transient increases in heart rate or localized injection site reactions.
National Institutes of Health (NIH) | (.gov)
Is cagrilintide better than retatrutide?
- Cagrilintide: A long-acting amylin analogue that slows stomach emptying and promotes a feeling of fullness. It is typically tested alongside the GLP-1 receptor agonist semaglutide.
Bolt Pharmacy +1
- Retatrutide: A single “triple-agonist” peptide that simultaneously targets GLP-1, GIP, and glucagon receptors to curb appetite, manage blood sugar, and increase calorie burning (energy expenditure).
Bolt Pharmacy
- Retatrutide: Phase 3 clinical data have shown remarkable weight reduction reaching up to roughly 28.7% of body weight, making it one of the most potent single agents studied for obesity.
- Cagrilintide (as CagriSema): Combined treatment of cagrilintide and semaglutide has shown robust weight loss around 20% to 23% in major trials, which is an improvement over older standard GLP-1 drugs, though trailing retatrutide’s peak trial numbers.
Longevity.Technology +1
- Cagrilintide alone: Produces lower standalone weight reduction (roughly 11%) compared to multi-agonist approaches.
YouTube·Dr. Dan | Obesity Expert
- Approval Status: Neither drug is fully licensed or universally approved for general commercial prescription as standard-of-care obesity treatment; both continue to be evaluated through ongoing clinical trial programs.
Bolt Pharmacy +1
- Side Effects: Both share common gastrointestinal side effects like nausea, vomiting, and diarrhea, though their distinct receptor profiles mean researchers track different specific secondary risks (such as heart rate changes with glucagon activity or gallbladder considerations with amylin combinations).
Bolt Pharmacy +2
For diluting lyophilized peptide powders, use a sterile and suitable research solvent such as bacteriostatic water (BAC), which may help support handling stability and reduce contamination risk.
For convenient laboratory use, see Bacteriostatic water 10ml.
Why Limitless Biochem?
Limitless BioChem is a trusted supplier of research compounds. Our products meet strict quality standards and are compliant with EU requirements. We focus on the safe and reliable supply of peptides and pure compounds intended exclusively for research or collector purposes.
- Peptides, Nootropics, Amino acids…
- Products tested by an independent laboratory
- Exclusively pure compounds without additives
- Worldwide Delivery
Warning
This product is not intended for human or veterinary use. It is for collection or research purposes only. It cannot be used as food, dietary supplement or medicine! The information provided in the text on this page is for educational purposes only and does not constitute medical or other advice.





Reviews
There are no reviews yet.